JP7382343B2 - Ｍｆａｐ４に対する抗体 - Google Patents

Ｍｆａｐ４に対する抗体 Download PDF

Info

Publication number
JP7382343B2
JP7382343B2 JP2020558681A JP2020558681A JP7382343B2 JP 7382343 B2 JP7382343 B2 JP 7382343B2 JP 2020558681 A JP2020558681 A JP 2020558681A JP 2020558681 A JP2020558681 A JP 2020558681A JP 7382343 B2 JP7382343 B2 JP 7382343B2
Authority
JP
Japan
Prior art keywords
mfap4
antibody
seq
amino acid
has0326
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020558681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513360A5 (https=
JP2021513360A (ja
Inventor
ルケ ソーレンセン グリス
スローサー アンダース
ホルモスコフ ウッフェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syddansk Universitet
Original Assignee
Syddansk Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syddansk Universitet filed Critical Syddansk Universitet
Publication of JP2021513360A publication Critical patent/JP2021513360A/ja
Publication of JP2021513360A5 publication Critical patent/JP2021513360A5/ja
Application granted granted Critical
Publication of JP7382343B2 publication Critical patent/JP7382343B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020558681A 2017-11-01 2018-11-01 Ｍｆａｐ４に対する抗体 Active JP7382343B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17199552 2017-11-01
EP17199552.5 2017-11-01
PCT/EP2018/079949 WO2019086580A1 (en) 2017-11-01 2018-11-01 Antibodies against mfap4

Publications (3)

Publication Number Publication Date
JP2021513360A JP2021513360A (ja) 2021-05-27
JP2021513360A5 JP2021513360A5 (https=) 2021-12-09
JP7382343B2 true JP7382343B2 (ja) 2023-11-16

Family

ID=60201899

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020558681A Active JP7382343B2 (ja) 2017-11-01 2018-11-01 Ｍｆａｐ４に対する抗体

Country Status (7)

Country Link
US (1) US11993649B2 (https=)
EP (1) EP3704147A1 (https=)
JP (1) JP7382343B2 (https=)
CN (1) CN111315771B (https=)
AU (1) AU2018359635B2 (https=)
CA (1) CA3118361A1 (https=)
WO (1) WO2019086580A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250282861A1 (en) * 2021-04-12 2025-09-11 Syddansk Universitet Mfap4 and treatment of fibrosis
WO2025242098A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体偶联药物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103157A1 (en) 2008-02-22 2009-08-27 University Health Network Mfap4 as a marker for regulatory cells and anti-cancer cells
JP2013018715A (ja) 2011-07-07 2013-01-31 Kao Corp Ｍｆａｐ−４産生促進剤
WO2014114298A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2016008498A1 (en) 2014-07-17 2016-01-21 Syddansk Universitet Mfap4 binding antibody blocking the interaction between mfap4 and integrin receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106771201A (zh) * 2016-12-05 2017-05-31 江西惠肽生物科技有限公司 用于肝纤维化诊断试剂盒及其检测方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103157A1 (en) 2008-02-22 2009-08-27 University Health Network Mfap4 as a marker for regulatory cells and anti-cancer cells
JP2013018715A (ja) 2011-07-07 2013-01-31 Kao Corp Ｍｆａｐ−４産生促進剤
WO2014114298A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2016008498A1 (en) 2014-07-17 2016-01-21 Syddansk Universitet Mfap4 binding antibody blocking the interaction between mfap4 and integrin receptors

Also Published As

Publication number Publication date
CN111315771A (zh) 2020-06-19
AU2018359635A1 (en) 2020-05-07
US20230047179A1 (en) 2023-02-16
US11993649B2 (en) 2024-05-28
CN111315771B (zh) 2023-10-27
AU2018359635A2 (en) 2020-05-21
AU2018359635B2 (en) 2024-11-14
CA3118361A1 (en) 2019-05-09
EP3704147A1 (en) 2020-09-09
WO2019086580A1 (en) 2019-05-09
JP2021513360A (ja) 2021-05-27

Similar Documents

Publication Publication Date Title
KR101774121B1 (ko) 이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도
WO2020019135A1 (zh) 一种抗cd47抗体及其应用
JP2022101694A (ja) ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
JP2013531470A5 (https=)
US20240343791A1 (en) Bispecific fusion polypeptide and application thereof
JP2020511946A (ja) グレムリン−１の結晶構造及び阻害抗体
JP2022514290A (ja) 改変抗体ｆｃおよび使用方法
KR20200138290A (ko) C3-결합제 및 이의 사용 방법
EP2734546A1 (en) Apelin antigen-binding proteins and uses thereof
WO2017119434A1 (ja) Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
JP7382343B2 (ja) Ｍｆａｐ４に対する抗体
US12509512B2 (en) Semaphorin 3A antibodies and uses thereof
JP6921943B2 (ja) 増加した眼球保持を伴う眼科用融合タンパク質
TW202246351A (zh) Htra1結合劑及其使用方法
AU2021304993B2 (en) Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof
US20240067711A1 (en) Anti-vegf hexameric antibody and composition comprising same
KR20250036852A (ko) Ang-2/vegf 항체 및 그의 용도
TWI914375B (zh) 含有補體路徑抑制物及血管生成抑制物的融合蛋白及其用途
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
KR20220029343A (ko) 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
WO2023083243A1 (zh) 一种抗il-17/vegf双功能融合蛋白及其用途
RU2022102753A (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
JP2021527679A (ja) 補体−アナフィラトキシン吸着薬、および眼の創傷および／または線維症を有する対象の治療におけるそれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201030

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231106

R150 Certificate of patent or registration of utility model

Ref document number: 7382343

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150